Abstract
With the advances in genomics, molecular biology including gene vector technologies todays molecular imaging modalities have strongly been improved. The major progress is based on peptide and antibody targeting vectors. When labeled with β-emitting radioisotopes these agents are applicable for endoradiotherapy and exploit the targeting potential for highly specific therapeutic applications. This novel class of pharmaceuticals offers the potential to develop patient specific therapies and might provide the means to go beyond the possibilities of current chemotherapy and radiation therapy. In this review the basic principles of endoradiotherapeutics based on peptides and proteins are presented. Several of these drugs such as 90Y-rituximab (Zevalin), 131I-tositumomab (Bexxar) and the somatostatin receptor binding 90YDOTATOC that are nowadays successfully applied in oncological therapy are discussed. Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries.
Keywords: Endoradiotherapy, oncology, labeling, radioisotopes, targeting
Protein & Peptide Letters
Title: Radiolabeled Peptides and Proteins in Cancer Therapy
Volume: 14 Issue: 3
Author(s): Carmen Wangler, Inga Buchmann, Michael Eisenhut, Uwe Haberkorn and Walter Mier
Affiliation:
Keywords: Endoradiotherapy, oncology, labeling, radioisotopes, targeting
Abstract: With the advances in genomics, molecular biology including gene vector technologies todays molecular imaging modalities have strongly been improved. The major progress is based on peptide and antibody targeting vectors. When labeled with β-emitting radioisotopes these agents are applicable for endoradiotherapy and exploit the targeting potential for highly specific therapeutic applications. This novel class of pharmaceuticals offers the potential to develop patient specific therapies and might provide the means to go beyond the possibilities of current chemotherapy and radiation therapy. In this review the basic principles of endoradiotherapeutics based on peptides and proteins are presented. Several of these drugs such as 90Y-rituximab (Zevalin), 131I-tositumomab (Bexxar) and the somatostatin receptor binding 90YDOTATOC that are nowadays successfully applied in oncological therapy are discussed. Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries.
Export Options
About this article
Cite this article as:
Wangler Carmen, Buchmann Inga, Eisenhut Michael, Haberkorn Uwe and Mier Walter, Radiolabeled Peptides and Proteins in Cancer Therapy, Protein & Peptide Letters 2007; 14 (3) . https://dx.doi.org/10.2174/092986607780090874
DOI https://dx.doi.org/10.2174/092986607780090874 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Malignant Hypercalcemia
Current Medicinal Chemistry Clinical Application of Ghrelin
Current Pharmaceutical Design miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Engineered Polymer Nanoplatforms for Targeted Tumor Cells and Controlled Release Cargos to Enhance Cancer Treatment
Current Medicinal Chemistry The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Patenting the Gene-Hubs of Endoplasmic Reticulum Stress: The Systems Biology Approach
Recent Patents on Biotechnology SUBJECT INDEX TO VOLUME 1
Current Medicinal Chemistry - Anti-Cancer Agents The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress
Current Molecular Medicine Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design PTD/CPP Peptide-Mediated Delivery of siRNAs
Current Pharmaceutical Design Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters Acute and Chronic Stress-Induced Disturbances of Microglial Plasticity, Phenotype and Function
Current Drug Targets HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Treatment of Hereditary Angioedema: Current Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Current Medical Imaging Recent Advances in Registration Methods for MRI-TRUS Fusion Image-Guided Interventions of Prostate
Recent Patents on Engineering Subject Index To Volume 6
Current Molecular Medicine Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets E2F1 and NF-κB: Key Mediators of Inflammation-associated Cancers and Potential Therapeutic Targets
Current Cancer Drug Targets